Preparation of DC-Chol and its adjuvant effect on HBsAg

Chinese Pharmaceutical Journal

Volumn 42, Issue 13, 2007, Pages 998-1002

  Yuan, You Cheng ^a   Yi, Xue Rui ^a   Yang, Jun ^a   Shi, Li ^a   Zeng, Ying ^b   Dong, Fu Min ^c   Kong, Xiang Ping ^a  

^a No 458 Hospital of PLA   (China)

^b Shenzhen Kangtai Biological Products Co Ltd   (China)

^c Department of Ophthalmology   (China)

Author keywords

Adjuvant; Dc chol; ELISA; ELISPOT; TLC

Indexed keywords

DIMETHYLAMINOETHANE CARBAMOYL CHOLESTEROL LIPOSOME; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; THIN LAYER CHROMATOGRAPHY;

EID: 34547220419     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. HORIIKE N, AKBAR M F, MICHITAKA K. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B [J]. J Clin Virol, 2005,32:156-161.
2. REN F Y, HINO K, YAMAGUCHI Y, et al. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection [J]. J Med Virol, 2003,71:376-384.
3. VILLARET D, GLISSON B, KENADY D, et al. A milticenter phase II study of tgDCC-E1 A for the intratumoral treatment of patients with recurrent head and squamous cell carcinoma [J]. Head Neck, 2002,24(7):661-669.
4. YI X R, ZU P, YUAN Y C, et al. Liposome adjuvant enhances the immunogenicity of hepatitis B vaccine [J]. Shanghai J Immunol, 2002,22(6):395-397.
5. PINK J R, KIENY M P. 4th meeting on novel adjuvants currently in/close to human clinical testing World Health Organization-Organisation Mondiale de la Santé Fondation Mérieux, Aannecy, France, 23-25 June 2003 [J]. Vaccine, 2004,22:2097-2102.
6. YUAN Y C, YI X R, ZU P, et al. Physicochemical property of a novel adjuvant and conjugate of it with HBsAg [J]. Chin J Biol, 2003,16(3):168-171.
7. BRUNO G, NICOLE P, ALAIN F, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine [J]. Vaccine, 2001,19:1794-1805.
8. BRUNEL F, DARBOURET A, RONCO J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine [J]. Vaccine, 1999,17:2192-2203.